An agonist of Ppar-γ enhanced the clearance of iRBCs of P. falciparum in vitro and improved the survival rate of mice infected with P. berghei and reduced parasitemia in the P. chabaudi chabaudi model in a CD36 dependent manner [31]. Here, PPARG is linked to parasitic infectious disease.